Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors.
Fiche publication
Date publication
septembre 2022
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr HENNEQUIN Audrey
Tous les auteurs :
Le Tourneau C, Becker H, Claus R, Elez E, Ricci F, Fritsch R, Silber Y, Hennequin A, Tabernero J, Jayadeva G, Luedtke D, He M, Isambert N
Lien Pubmed
Résumé
BI 836880 is a humanized bispecific nanobody® that inhibits vascular endothelial growth factor and angiopoietin-2. Here, we report results from two phase I, nonrandomized, dose-escalation studies (NCT02674152 and NCT02689505; funded by Boehringer Ingelheim) evaluating BI 836880 in patients with confirmed locally advanced or metastatic solid tumors, refractory to standard therapy, or for which standard therapy was ineffective.
Mots clés
Vascular endothelial growth factor, advanced solid tumors, angiopoietin-2, nanobody, phase I
Référence
ESMO Open. 2022 09 12;7(5):100576